Wealthquest Corp Takes Position in Repligen Corporation (NASDAQ:RGEN)

Wealthquest Corp bought a new stake in Repligen Corporation (NASDAQ:RGEN - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor bought 2,077 shares of the biotechnology company's stock, valued at approximately $264,000.

A number of other institutional investors and hedge funds also recently modified their holdings of RGEN. CIBC Asset Management Inc raised its holdings in Repligen by 5.0% in the 4th quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company's stock valued at $246,000 after acquiring an additional 81 shares during the period. Utah Retirement Systems raised its holdings in Repligen by 1.1% in the 4th quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company's stock valued at $1,338,000 after acquiring an additional 100 shares during the period. Peapack Gladstone Financial Corp raised its holdings in Repligen by 5.2% in the 4th quarter. Peapack Gladstone Financial Corp now owns 2,089 shares of the biotechnology company's stock valued at $301,000 after acquiring an additional 103 shares during the period. Signaturefd LLC raised its holdings in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 124 shares during the period. Finally, Arizona State Retirement System raised its holdings in Repligen by 0.8% in the 4th quarter. Arizona State Retirement System now owns 15,410 shares of the biotechnology company's stock valued at $2,218,000 after acquiring an additional 126 shares during the period. 97.64% of the stock is owned by institutional investors.

Repligen Stock Performance

NASDAQ RGEN opened at $123.35 on Wednesday. The company has a current ratio of 6.79, a quick ratio of 5.79 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $6.93 billion, a price-to-earnings ratio of -274.11, a P/E/G ratio of 3.44 and a beta of 1.10. The firm's 50 day simple moving average is $128.50 and its 200 day simple moving average is $141.55. Repligen Corporation has a 1 year low of $102.97 and a 1 year high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.35 by $0.04. The business had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The firm's revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter last year, the business posted $0.28 EPS. As a group, research analysts expect that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on RGEN shares. JPMorgan Chase & Co. lowered their price target on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. Wolfe Research raised shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target on the stock in a report on Tuesday, April 29th. HC Wainwright reissued a "buy" rating and issued a $180.00 price target on shares of Repligen in a report on Monday, May 5th. Wall Street Zen raised shares of Repligen from a "hold" rating to a "buy" rating in a report on Saturday. Finally, Barclays began coverage on shares of Repligen in a report on Tuesday. They set an "overweight" rating and a $150.00 target price on the stock. Four analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $171.46.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.